Location History:
- Merion, PA (US) (2000 - 2002)
- Philadelphia, PA (US) (2020)
- Merion Station, PA (US) (2022)
Company Filing History:
3 out of 528 
2 out of 810 
Years Active: 2000-2022
Title: The Innovative Contributions of Laurence C. Eisenlohr
Introduction
Laurence C. Eisenlohr is a notable inventor based in Merion Station, PA (US). He has made significant contributions to the field of antiviral research, particularly in the development of therapeutic agents for drug-resistant influenza A. With a total of 4 patents to his name, Eisenlohr's work has the potential to impact public health positively.
Latest Patents
Eisenlohr's latest patents include groundbreaking work on antiviral agents for drug-resistant influenza A. One of his patents describes an effective therapeutic agent for the M2 channel, which comprises sulfonylamide or oxabicyclo structures. This agent is designed to treat amantadine-resistant influenza A infections. Another patent focuses on similar therapeutic agents and methods for treating these infections through administration of the same compounds.
Career Highlights
Throughout his career, Eisenlohr has worked with esteemed institutions such as Thomas Jefferson University and Ramot at Tel Aviv University Ltd. His research has been pivotal in addressing the challenges posed by drug-resistant strains of influenza, showcasing his commitment to advancing medical science.
Collaborations
Eisenlohr has collaborated with notable colleagues, including Michael J. Mastrangelo and Edmund C. Lattime. These partnerships have further enriched his research and contributed to the development of innovative solutions in the field of virology.
Conclusion
Laurence C. Eisenlohr's contributions to antiviral research and his innovative patents highlight his role as a significant figure in the fight against drug-resistant influenza A. His work continues to inspire advancements in medical treatments and public health initiatives.